Jump to content


Second-Generation TKIs Can Be Stopped in Many CML Patients

  • Please log in to reply
No replies to this topic

#1 scuba


    Advanced Member

  • Members
  • PipPipPip
  • 1,044 posts
  • LocationHouston, Texas

Posted 27 February 2017 - 08:12 AM



"The notion that TKIs may never be stopped was successfully challenged in imatinib-treated patients with deep and sustained molecular responses," wrote study authors led by Delphine Rea, MD, PhD, of Hôpital Saint-Louis in Paris. Second-generation TKIs induce higher rates of deep responses and a more rapid decline in BCR-ABL1 transcript levels compared with imatinib in newly diagnosed patients. "These data suggest that the use of dasatinib or nilotinib may increase opportunities to attempt treatment cessation in comparison with imatinib."

Diagnosed 11 May 2011 (100% FiSH, 155% PCR)

with b2a2 BCR-ABL fusion transcript coding for the 210kDa BCR-ABL protein


Sprycel: 20 mg per day - taken at lights out with Quercetin and/or Magnesium Taurate

6-8 grams Curcumin C3 complex.


2015 PCR: < 0.01% (M.D. Anderson scale)

2016 PCR: < 0.01% (M.D. Anderson scale) 

March        2017 PCR:     0.01% (M.D. Anderson scale)

June          2017 PCR:     "undetected"

September 2017 PCR:     "undetected"

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users